Moreover, MET/HER2 amplification and RAS-mitogen-activated protein kinase can be other resistance mechanisms to osimertinib in NSCLC patients with positive T790M [27]; therefore, comprehensive genomic testing for these resistance mechanisms should be performed, and adequate treatment should be provided to achieve better survival outcomes. Here, MET is linked to non-small cell lung carcinoma.